Alexandra Barranco

Alexandra Barranco

Auto-generated profile, based on publicly available information

Alexandra Barranco

Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2026 in Science
Verified
Journal Article
Open access
ACAlejandro Collado-Sole
Alejandro Collado-Sole
Nozha BorjiniNozha Borjini
Nozha Borjini
JZJing Zhai
Jing Zhai
FRFrancisco Ruiz-Pino
Francisco Ruiz-Pino
GSGonzalo Soria-Alcaide
Gonzalo Soria-Alcaide
EGEva González-Suárez
Eva González-Suárez
The hypothalamic-pituitary-gonadal axis (HPG) controls pubertal development, sexual maturation, and fertility. We identified a role of hypothalamic microglia in controlling the HPG axis through receptor activator of nuclear factor κB (Rank) signaling. Whole-body and microglia Rank (mouse) depletion led to hypogonadotropic hypogonadism (HH) resulting from an alteration in gonadotropin-releasing hormone (GnRH) neuron function. In addition, we identified rare gene variants of RANK (human) in patients with HH. Transcriptional profiling upon Rank loss revealed defective microglia activation and morphological alterations in the median eminence, decreasing the contacts and engulfment of GnRH terminal projections and impairing GnRH neuronal responses to kisspeptin. Overall, our data uncover the microglia as regulator of GnRH neuronal function through Rank signaling, with potential implications for reproductive maturation and fertility.

9 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MCMario Rodriguez-Del Collado
Mario Rodriguez-Del Collado
AVAndrea Carolina Vethencourt
Andrea Carolina Vethencourt
ABAlexandra Barranco
Alexandra Barranco
JVJaime Martinez de Villarreal
Jaime Martinez de Villarreal
DLDavid Valcárcel Linares
David Valcárcel Linares
EGEva González-Suárez
Eva González-Suárez
Hormone receptor-positive, HER2-negative breast cancers are often poorly infiltrated by immune cells and derive limited benefit from current immunotherapy strategies. Here, using paired tumour samples from the randomised window-of-opportunity D-BIOMARK trial ( NCT03691311 ), we investigated the immunomodulatory effects of denosumab in early luminal breast cancer. Short-term preoperative denosumab reduced tumour-cell proliferative transcriptional programs and immunosuppressive features of the local tumour microenvironment, enhancing innate and adaptive immune activation and altering circulating cytokine profiles. High-resolution spatial transcriptomics revealed coordinated remodelling of tumour, immune, fibroblast and endothelial compartments after treatment. Denosumab reduced immune–tumour spatial separation and enhanced T cell activation, accompanied by a shift from matrix-associated tumour programs towards increased tumour–T cell communication. Copy number-informed tumour-state inference further identified a reduced representation of genomically complex, immune-poor tumour subclones after treatment. Together, these findings identify denosumab as a modulator of tumour–microenvironment crosstalk and support RANKL blockade as a strategy to render immune-poor luminal breast tumours more permissive to immune engagement.